Status:
COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Lead Sponsor:
China Medical University Hospital
Conditions:
Schizophrenias
Psychoses
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients. The purp...
Detailed Description
The etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. In addition to dopamine system hyperactivity, hypofunction...
Eligibility Criteria
Inclusion
- Are physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
- Aged 18-65 year
- Fulfill the criteria of schizophrenia according to the Diagnostic and Statistical Manual, fourth edition (DSM-IV)
- Remain symptomatic but without clinically significant fluctuation and the antipsychotic doses are unchanged for at least 3 months
- Have a minimum baseline total score of 60 on the Positive and Negative Syndrome Scale (PANSS)
- Agree to participate in the study and provide informed consent
Exclusion
- DSM-IV diagnosis of substance (including alcohol) abuse or dependence,
- DSM\_IV diagnosis of mental retardation
- History of epilepsy, head trauma or CNS diseases
- History of epilepsy, head trauma or CNS diseases
- Pregnancy or lactation
- Inability to follow protocol
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00960219
Start Date
April 1 2009
End Date
July 1 2011
Last Update
July 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan